Angina Advice

Intravascular Ultrasound   by jekky

Advantages over Angiography

Arguably the most valuable use of IVUS is to visualize plaque, which cannot be seen by angiography. It has been increasingly used in research to better understand the behavior of the atherosclerosis process in living people. Based on the angiographic view and long popular medical beliefs, it had long been assumed that areas of high grade stenosis (narrowing) of the lumen (opening) within the coronary arteries, visible by angiography, were the likely points at which most myocardial infarctions (heart attacks) would occur. Research using IVUS has helped to reveal the fallacy (in most instances) of this belief.

IVUS enables accurately visualizing not only the lumen of the coronary arteries but also the atheroma (membrane/cholesterol loaded white blood cells) “hidden” within the wall. IVUS has thus enabled advances in clinical research providing a more thorough perspective and better understanding.

In the early 1990s, IVUS research on the re-stenosis problem after angioplasty lead to recognition that most of the re-stenosis problem (as visualized by an angiography examination) was not true re-stenosis. Instead it was simply a remodeling of the atheromatous plaque, which was still protruding into the lumen of the artery after completion of angioplasty; the stenosis only appearing to be reduced because blood and contrast could now flow around and through some of the plaque. The angiographic dye column appeared widened adequately; yet considerable plaque was within the newly widened lumen and the lumen remained partially obstructed. This recognition promoted more frequent use of stents to hold the plaque outward against the inner artery walls, out of the lumen.

Additionally, IVUS examinations, as they were done more frequently, served to reveal and confirm the autopsy research findings of the late 1980s, showing that atheromatous plaque tends to cause expansion of the internal elastic lamina, causing the degree of plaque burden to be greatly underestimated by angiography. Angiography only reveals the edge of the atheroma that protrudes into the lumen.

Intravascular ultrasound image of a coronary artery (left), with color coding on the right, delineating the lumen (yellow), external elastic membrane (blue) and the atherosclerotic plaque burden (green). The percentage stenosis is defined as the area of the lumen (yellow) divided by the area of the external elastic membrane (blue) times 100. As the plaque burden increases, the lumen size will decrease and the degree of stenosis will increase.

Perhaps the greatest contribution to understanding, so far, was achieved by clinical research trials completed in the United States in the late 1990s, using combined angiography and IVUS examination, to study which coronary lesions most commonly result in a myocardial infarction.[citation needed] The studies revealed that most myocardial infarctions occur at areas with extensive atheroma within the artery wall, however very little stenosis of the artery opening.[citation needed] The range of lumen stenosis locations at which myocardial infarctions occurred ranged from areas of mild dilatation all the way to areas of greater than 95% stenosis. However the average or typical stenosis at which myocardial infarctions occurred were found to be less than 50%[citation needed], describing plaques long considered insignificant by many. Only 14% of heart attacks occurred at locations with 75% or more stenosis[citation needed], the severe stenoses previously thought by many to present the greatest danger to the individual. This research has changed the primary focus for heart attack prevention from severe narrowing to vulnerable plaque.

Current clinical uses of IVUS technology include checking how to treat complex lesions before angioplasty and checking how well an intracoronary stent has been deployed within a coronary artery after angioplasty. If a stent is not expanded flush against the wall of the vessel, turbulent flow may occur between the stent and the wall of the vessel; some fear this might create a nidus for acute thrombosis of the artery.

Disadvantages versus angiography

The primary disadvantages of IVUS being used routinely in a cardiac catheterization laboratory are its expense, the increase in the time of the procedure, and the fact that it is considered an interventional procedure, and should only be performed by angiographers that are trained in interventional cardiology techniques. In addition, there may be additional risk imposed by the use of the IVUS catheter.

The computerized IVUS echocardiographic imaging systems list for $120,000, US, 2007 for a cart based system and ~$70,000 for an installed or integrated solution. The disposable catheters used to do each examination typically cost ~$600, US, 2007. In many hospitals, the IVUS system is placed as part of a bundle deal based on minimum disposable sales volumes. In other words, the cost of the console is paid for by rebates from other purchased products including IVUS catheters. Because no standard exists, IVUS catheters cannot be interchanged between different manufacturers.

Additionally, IVUS adds significant additional examination time and some increased risk to the patient beyond performing a standard diagnostic angiographic examination. This increase is significantly less when IVUS is part of a percutaneous coronary intervention, since much of the setup is the same for the intervention as for the IVUS imaging.

IVUS continues to improve and some manufacturers have proposed building IVUS technology into angioplasty and stent balloon catheters, a potential major advance, but limited by complexity, cost and increased bulk of the catheters.

Method

To visualize an artery or vein, angiographic techniques are used and the physician positions the tip of a guidewire, usually 0.36 mm (0.014″) diameter with a very soft and pliable tip and about 200 cm long. The physician steers the guidewire from outside the body, through angiography catheters and into the blood vessel branch to be imaged.

The ultrasound catheter tip is slid in over the guidewire and positioned, using angiography techniques so that the tip is at the farthest away position to be imaged. The sound waves are emitted from the catheter tip, are usually in the 10-20 MHz range, and the catheter also receives and conducts the return echo information out to the external computerized ultrasound equipment which constructs and displays a real time ultrasound image of a thin section of the blood vessel currently surrounding the catheter tip, usually displayed at 30 frames/second image.

The guide wire is kept stationary and the ultrasound catheter tip is slid backwards, usually under motorized control at a pullback speed of 0.5 mm/s. (The motorized pullback tends to be smoother than hand movement by the physician.)

The (a) blood vessel wall inner lining, (b) atheromatous disease within the wall and (c) connective tissues covering the outer surface of the blood vessel are echogenic, i.e. they return echoes making them visible on the ultrasound display.

By contrast, the blood itself and the healthy muscular tissue portion of the blood vessel wall is relatively echolucent, just black circular spaces, in the images.

Heavy calcium deposits in the blood vessel wall both heavily reflect sound, i.e. are very echogenic, but are also distinguishable by shadowing. Heavy calcification blocks sound transmission beyond and so, in the echo images, are seen as both very bright areas but with black shadows behind (from the vantage point of the catheter tip emitting the ultrasound waves).

Uses

IVUS, as outlined above, has been the best technology, so far, to demonstrate the anatomy of the artery wall in living animals and humans. It has led to an explosion of better understanding and research on both (a) the behavior of the atherosclerosis process and (b) the effects of different treatment strategies for changing the evolution of the atherosclerosis disease process. This has been important given that atherosclerosis is the single most frequent disease process for the greatest percentage of individuals living in first world countries.

Intravascular ultrasound in the coronary anatomy

An IVUS image of the ostial left main coronary artery (left). The blue outline delineates the cross-sectional area of the lumen of the artery (A1 in the upper right corner), measuring 6.0 mm2. A 2-dimensional mapping of the proximal LAD and left main coronary arteries is shown on the right.

While the routine use of IVUS during percutaneous coronary intervention does not improve short term outcomes, there are a number of situations in which IVUS is of particular use in the treatment of coronary artery disease of the heart. In particular in cases when the degree of stenosis of a coronary artery is unclear, IVUS can directly quantify the percentage of stenosis and give insight into the anatomy of the plaque.

One particular use of IVUS in the coronary anatomy is in the quantification of left main disease in cases where routine coronary angiography gives equivocal results. Many studies in the past have shown that significant left main disease can increase mortality, and that intervention (either coronary artery bypass graft surgery or percutaneous coronary intervention) to reduce mortality is necessary when the left main stenosis is significant.

When using IVUS to determine whether an individual’s left main disease is clinically significant, in terms of the desirability of physical intervention, the two most widely used parameters are the degree of stenosis and the minimal lumen area. A cross sectional area of 7 mm in a symptomatic individual[citation needed] or 6 mm in an asymptomatic individual is considered to be clinically significant and warrants intervention to improve one-year mortality. However, these exact cutoffs are up for debate and different cutoff cross-sectional areas may be used in practice depending on differing interpretations of the trial data.

Validating the efficacy of new treatments

Because IVUS is widely available in coronary catheterization labs worldwide and can accurately quantify arterial plaque, especially within the coronary arteries, it is increasingly being used to evaluate newer and evolving strategies for the treatment of coronary artery disease, including the statins, torcetrapib and other approaches.

References

^ Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. (1987). “Compensatory enlargement of human atherosclerotic coronary arteries”. N Engl J Med 316 (22): 13715. PMID 3574413. 

^ Zarins CK, Weisenberg E, Kolettis G, Stankunavicius R, Glagov S. (1988). “Differential enlargement of artery segments in response to enlarging atherosclerotic plaques”. J Vasc Surg 7 (3): 38694. doi:10.1067/mva.1988.avs0070386. PMID 3346952. 

^ Schiele F, Meneveau N, Vuillemenot A, Zhang DD, Gupta S, Mercier M, Danchin N, Bertrand B, Bassand JP. (1998). “Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies–with and without intravascular ultrasound guidance”. J Am Coll Cardiol 32 (2): 3208. doi:10.1016/S0735-1097(98)00249-6. PMID 9708456. 

^ Abizaid AS, Mintz GS, Abizaid A, Mehran R, Lansky AJ, Pichard AD, Satler LF, Wu H, Kent KM, Leon MB (1999). “One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms”. J Am Coll Cardiol 34 (3): 70715. doi:10.1016/S0735-1097(99)00261-2. PMID 10483951. 

^ Robert D. Safian, MD, Mark S. Freed, MD, ed (2002). “Intravascular Ultrasound”. The Manual Of Interventional Cardiology (Third ed.). Royal Oak, Michigan: Physicians’ Press. pp. 712. ISBN 1-890114-39-1. 

^ Jasti V, Ivan E, Yalamanchili V, Wongpraparut N, Leesar MA. (2004). “Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis”. Circulation 110 (18): 28316. doi:10.1161/01.CIR.0000146338.62813.E7. PMID 15492302. 

^ Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. url=http://jama.ama-assn.org/cgi/reprint/jama;295/13/1556.pdf?ijkey=Md42dlk7z9TzyL8&keytype=finite JAMA 2006;295:1556-65. PMID 16533939.

^ Nissen SE (2002). “Who is at risk for atherosclerotic disease? Lessons from intravascular ultrasound”. Am J Med 112 (Suppl 8a): 27S33S. doi:10.1016/S0002-9343(02)01087-2. PMID 12049992. 

^ Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. (2003). “Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes”. JAMA 290 (17): 22922300. doi:10.1001/jama.290.17.2292. PMID 14600188. 

See also

Fractional flow reserve

External links

Intravascular Ultrasound Center from Angioplasty.Org

Reprint of ASTEROID Study, JAMA 2006;295:1556-65: This trial relies on IVUS for assessment of medical treatment.

iLab Ultrasound Imaging System from Boston Scientific

Categories: Cardiology | Medical imaging | Medical ultrasoundHidden categories: Articles needing additional references from September 2009 | All articles needing additional references | All articles with unsourced statements | Articles with unsourced statements from February 2007

About the Author

I am an expert from China Crafts Suppliers, usually analyzes all kind of industries situation, such as painted aluminum sheet, bale tie wire.
Modifying the Progression of Atherosclerosis

High cholesterol levels Photo Mugs High cholesterol levels. Computer artwork of red blood cells and balls of cholesterol (yellow) in a blood vessel. When there are high levels of low density lipoprotein (LDL) cholesterol in the blood it builds up on the sides of blood vessels hardening them, a condition named atherosclerosis. This narrows the blood vessels and may even block them, causing a heart attack if the blocked vessel is in …

High cholesterol levels Photo Mugs High cholesterol levels. Computer artwork of balls of cholesterol in a blood vessel. When there are high levels of low density lipoprotein (LDL) cholesterol in the blood it builds up on the sides of blood vessels hardening them, a condition named atherosclerosis. This narrows the blood vessels and may even block them, causing a heart attack if the blocked vessel is in the heart, or a stroke if it …

Dyslipidemia: Getting Your Cholesterol Under Control (Home Use) $24.95 Part of the award winning public television series Healthy Body/Healthy Mind. Dyslipidemia occurs when there are abnormal amounts of lipids (fats) or lipoproteins (cholesterol) in the blood. This program will educate the audience about Dyslipidemia and Cholesterol Management and will focus on risk assessment (blood test, family history, imaging, etc.). The program will also discuss what patients c…

Dyslipidemia: Getting Your Cholesterol Under Control (Educational Use) $120.00 Part of the award winning public television series Healthy Body/Healthy Mind. Dyslipidemia occurs when there are abnormal amounts of lipids (fats) or lipoproteins (cholesterol) in the blood. This program will educate the audience about Dyslipidemia and Cholesterol Management and will focus on risk assessment (blood test, family history, imaging, etc.). The program will also discuss what patients c…

The Cholesterol Wars: The Skeptics vs the Preponderance of Evidence $59.99 Today, in the era of the statins (cholesterol lowering drugs), there is no longer any doubt about the value of lowering blood cholesterol levels. This book chronicles the controversy that swirled around the ‘lipid hypothesis’ of atherosclerosis for so many years. In fact, ‘the lower the better’ is the position of many clinicians. However, getting to this point has been a long uphill battle marked …

The many faces of Statins. (Heart of the Matter).: An article from: Internal Medicine News $5.95 This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2002. The length of the article is 612 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation…

Intensive statin regimen may halt atherosclerosis: measured by intravascular ultrasound: ‘maximally intensive … therapy can completely halt the … An article from: Family Practice News $5.95 This digital document is an article from Family Practice News, published by International Medical News Group on December 15, 2003. The length of the article is 774 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation…

Photo Jigsaw Puzzle of High cholesterol levels from Science Photo Library Photo Puzzle, High cholesterol levels. High cholesterol levels. Computer artwork of red blood cells and balls of cholesterol (yellow) in a blood vessel. When there are high levels of low density lipoprotein (LDL) cholesterol in the blood it builds up on the sides of blood vessels hardening them, a condition named atherosclerosis. This narrows the blood vessels and may even block them, causing a he…

Photo Jigsaw Puzzle of High cholesterol levels from Science Photo Library Photo Puzzle, High cholesterol levels. High cholesterol levels. Computer artwork of balls of cholesterol in a blood vessel. When there are high levels of low density lipoprotein (LDL) cholesterol in the blood it builds up on the sides of blood vessels hardening them, a condition named atherosclerosis. This narrows the blood vessels and may even block them, causing a heart attack if the blocked ves…

Lipids and Atherosclerosis Annual 2003 by Gaw, Dr Allan; Shephard, James Edition , 2 $32.05 This latest edition of the Lipids and Atherosclerosis Annual includes chapters on topics of current interest, including the long-term safety of lipid-lowering drugs and the implications of statin therapy on CHD prevention.

Atherosclerosis $58.5 No Synopsis Available

HP 73" Docking Statin Cable Lock AU656AAR#ABA $72.34 HP 73" Docking Statin Cable Lock AU656AAR#ABA

Statin Prescribing Guide $14.28 No Synopsis Available

Intracranial Atherosclerosis $154.18 No Synopsis Available

Platelets and Atherosclerosis $61.38 No Synopsis Available

Atherosclerosis and Arteriosclerosis $497.25 No Synopsis Available

Atherosclerosis Reviews $87.75 No Synopsis Available

Hyperlipidaemia and Atherosclerosis $63.38 No Synopsis Available

Atlas of Atherosclerosis $96.53 No Synopsis Available

Atherosclerosis : Is It Reversible? $29.25 No Synopsis Available

Diabetes and Atherosclerosis $408.53 No Synopsis Available

Pathology of Atherosclerosis $82.88 No Synopsis Available

Statin Prescribing Guide by Baliga, MD, Ragavendra R Edition , 1 $20.49 The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere.As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. As a class, they are well-tolerated by most patients and are easy to administer. However, the withdrawal of cerivastatin (Baycol) from the market in 2001 due to severe myopathy in some patients, has led to increased concern among clinicians with respect to this and other side effects, such as liver and kidney disease. Some studies suggest that this has led to increased reluctance among clinicians to initiate a statin drug regimen or to adjust dosage to increase therapeutic effect. While a small minority of patients do develop serious complications while on statin therapy, current clinical evidence strongly suggests that the benefits of timely statin administration significantly outweigh the risks.Oxford American Pocket Notes: Statin Prescribing Guide aims to provide clinicians with concise, easily accessible guidance on prescribing statins in various clinical settings. This volume features evidence-based discussion on the indications, pharmacokinetics and safety profiles of the available statins and how these properties translate into selection of the appropriate treatment regimen for the individual patient. Useful tools, such as treatment algorithms, charts, tables and illustrations greatly help enhance the value of this volume as a portable reference tool.

Statin Prescribing Guide by Baliga, MD, Ragavendra R Edition ILL, 1 $22.49 The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere.As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. As a class, they are well-tolerated by most patients and are easy to administer. However, the withdrawal of cerivastatin (Baycol) from the market in 2001 due to severe myopathy in some patients, has led to increased concern among clinicians with respect to this and other side effects, such as liver and kidney disease. Some studies suggest that this has led to increased reluctance among clinicians to initiate a statin drug regimen or to adjust dosage to increase therapeutic effect. While a small minority of patients do develop serious complications while on statin therapy, current clinical evidence strongly suggests that the benefits of timely statin administration significantly outweigh the risks.Oxford American Pocket Notes: Statin Prescribing Guide aims to provide clinicians with concise, easily accessible guidance on prescribing statins in various clinical settings. This volume features evidence-based discussion on the indications, pharmacokinetics and safety profiles of the available statins and how these properties translate into selection of the appropriate treatment regimen for the individual patient. Useful tools, such as treatment algorithms, charts, tables and illustrations greatly help enhance the value of this volume as a portable reference tool.

Asymptomatic Atherosclerosis by Naghavi, Morteza Edition ILL, 1 $121.99 Despite recent advances in the diagnosis and treatment of symptomatic atherosclerosis, available traditional screening methods for early detection and treatment of asymptomatic coronary artery disease are grossly insufficient and fail to identify the majority of victims prior to the onset of a life-threatening event. In Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment, Dr. Morteza Naghavi and leading authorities from the Society for Heart Attack Prevention and Eradication (SHAPE) present a new paradigm for the screening and primary prevention of asymptomatic atherosclerosis. The text focuses on accurate, yet underutilized, measures of subclinical atherosclerosis, notably coronary artery calcium scanning and carotid intima-media thickness measurement. The authors introduce a comprehensive approach to identifying the vulnerable patients (asymptomatic individuals at risk of a near future adverse event). Additional chapters discuss future directions towards containing the epidemic of atherosclerotic cardiovascular disease using innovative solutions such as preemptive interventional therapies (bioabsorbable stents) for stabilization of vulnerable atherosclerotic plaques, mass unconditional Polypill therapy for population-based risk reduction, and ultimately vaccination strategies to prevent the development of atherosclerosis. Up-to-date and authoritative, Asymptomatic Atherosclerosis: Pathophysiology, Detection, and Treatment is a must-have for any cardiologist or primary care physician who wishes to practice modern preventive cardiology and manage the increasing number of asymptomatic atherosclerotic patients. Outlines more accurate measures of risk (coronary artery calcium and carotid intima-media thickness) than traditional risk factors (total cholesterol, LDL cholesterol, HDL cholesterol) Presents new multipronged strategies to aid in the early detection and treatment of high risk asymptomatic patients

Atlas of Atherosclerosis and Metabolic Syndrome $171.03 No Synopsis Available

Atherosclerosis Disease Management $228.36 No Synopsis Available

Atherosclerosis : Molecular and Cellular Mechanisms $181.49 No Synopsis Available

Lipids and Atherosclerosis Annual 2001 $85.82 No Synopsis Available

Lipids and Atherosclerosis Annual 2003 $95.9 No Synopsis Available

Dietary Proteins and Atherosclerosis $201.74 No Synopsis Available

Lipids and Atherosclerosis Annual 2003 $32.84 Used – This latest edition of the “Lipids and Atherosclerosis Annual” includes chapters on topics of current interest, including the long-term safety of lipid-lowering drugs and the implications of statin therapy on CHD prevention.

Lipids and Atherosclerosis Annual 2003 $32.84 New – This latest edition of the “Lipids and Atherosclerosis Annual” includes chapters on topics of current interest, including the long-term safety of lipid-lowering drugs and the implications of statin therapy on CHD prevention.

Lipids and Atherosclerosis Annual 2003 $51.51 Used – This latest edition of the “Lipids and Atherosclerosis Annual” includes chapters on topics of current interest, including the long-term safety of lipid-lowering drugs and the implications of statin therapy on CHD prevention.

Lipids and Atherosclerosis Annual 2003 $51.51 New – This latest edition of the “Lipids and Atherosclerosis Annual” includes chapters on topics of current interest, including the long-term safety of lipid-lowering drugs and the implications of statin therapy on CHD prevention.

Red Yeast Rice Complex 60 Caps by Maxi-Health Research $14.74 Red Yeast Rice with Policosanol Supports and maintains healthy cholesterol levels Red yeast rice is a food product created by fermenting rice with a strain of red yeast. Recently red yeast rice extract, taken in supplement form, has been found both to reduce overall blood cholesterol levels and improve the HDL (good cholesterol) LDL (to bad cholesterol). A study conducted by the University of California, found that people who took red yeast rice and maintained a low fat diet reduced there overall cholesterol levels by an average of 40 points over a period of 12 weeks. Policosanol is a natural mixture of higher aliphatic primary alcohols which can either be derived from sugar cane or bees wax. Research shows that policosanol from sugar cane has a better effect on cholesterol levels than policosanol from bees wax. Policosanol is indicated as an adjunct to dietary recommendations to reduce LDL-C and Total Cholesterol Levels (Type II hypercholesterolemia) as in Atherosclerosis and Cardiovascular conditions, without any unsafe side affects caused by statins and medications. Policosinol works by slowing down the production of cholesterol in the liver while increasing the livers ability to reabsorb LDL. Unlike statin drugs that are usually used to lower elevated cholesterol levels, policosanol does not inhibit the HMG-CoA enzyme. For an overall healthy cardiovascular system try this great product. For more on the health benefits of Policosanol